Carcinotech Ltd

Carcinotech has pioneered the development of assay-ready, 3D-bioprinted tumours derived from patient biopsies for oncology drug discovery and development. Carcinotechs tumours are uniquely engineered to preserve cancer heterogeneity by encompassing multiple cell types present in the donor tumour microenvironment, including cancer, stromal, specialized microenvironment, immune, and cancer stem cells. This physiologically and genetically relevant model offers superior predictive power compared to traditional organoid and animal models, improving drug discovery, optimization, and pre-clinical testing efficiencies, thereby shortening the path to bringing a new oncology therapy to market

Precision oncology,cancer research,3d bioprinting ,drug discovery ,cancer microenvironment,personalised medicine testing,drug testing,oncology,assay services,biobank,oncology pre-clinical services,solid tumours,solid tumors,tumour microenvironment,tumor microenvironment,immuno-oncology,early phase drug development,and immune cells

Carcinotech ltd operates in the Biotechnology research industry.

Carcinotech ltd's revenue is 1m - 10m

Carcinotech ltd has 11 - 50 employees.